Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gene Cutler

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Plos Pathogens|January 13, 2022
EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22Aparna Jorapur, Lisa A Marshall, Scott Jacobson, et al.
Journal for Immunotherapy of Cancer|November 27, 2020
Tumors establish resistance to immunotherapy by regulating T<sub>reg</sub> recruitment via CCR4Lisa A Marshall, Sachie Marubayashi, Aparna Jorapur, et al.
Journal of Medicinal Chemistry|July 16, 2020
Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint InhibitorsOmar Robles, Jeffrey J Jackson, Lisa Marshall, et al.
Molecular Cancer Therapeutics|August 14, 2020
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity <i>In Vitro</i> and <i>In Vivo</i>Yamini M Ohol, Michael T Sun, Gene Cutler, et al.
Journal of Medicinal Chemistry|July 2, 2019
Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T<sub>reg</sub> Trafficking into the Tumor MicroenvironmentJeffrey J Jackson, John M Ketcham, Ashkaan Younai, et al.
Journal of Medicinal Chemistry|September 20, 2022
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis TherapyJeffrey J Jackson, Grant M Shibuya, Buvana Ravishankar, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Plos Pathogens|January 13, 2022
EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22Aparna Jorapur, Lisa A Marshall, Scott Jacobson, et al.
Journal for Immunotherapy of Cancer|November 27, 2020
Tumors establish resistance to immunotherapy by regulating T<sub>reg</sub> recruitment via CCR4Lisa A Marshall, Sachie Marubayashi, Aparna Jorapur, et al.
Journal of Medicinal Chemistry|July 16, 2020
Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint InhibitorsOmar Robles, Jeffrey J Jackson, Lisa Marshall, et al.
Molecular Cancer Therapeutics|August 14, 2020
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity <i>In Vitro</i> and <i>In Vivo</i>Yamini M Ohol, Michael T Sun, Gene Cutler, et al.
Journal of Medicinal Chemistry|July 2, 2019
Discovery of a Potent and Selective CCR4 Antagonist That Inhibits T<sub>reg</sub> Trafficking into the Tumor MicroenvironmentJeffrey J Jackson, John M Ketcham, Ashkaan Younai, et al.
Journal of Medicinal Chemistry|September 20, 2022
Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis TherapyJeffrey J Jackson, Grant M Shibuya, Buvana Ravishankar, et al.
Pageof 2